Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostAuthored by Chris Markoch. Published: 2/5/2026. 
In Brief - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion. On the bottom line, Pfizer delivered adjusted earnings per share (EPS) of $0.69, beating estimates of $0.57. Highlighting the report was Pfizer's announcement of positive topline results from the Phase 2b study for its lead GLP-1 candidate. Most people have no idea this is happening, but AI could gut the funding base for Social Security by the end of 2027. That means the checks millions of American seniors depend on just to get by could be cut in half or vanish completely, leaving retirees with no way to pay their bills. A former $4 billion hedge fund legend has seen what's coming and put together a presentation detailing exactly how AI could collapse the funding base for Social Security and what to do as AI turns the economy upside down. See his three recommended moves before it's too late PFE stock closed up 4% on Feb. 4 as analysts and investors digested the report. The bullish thesis is that while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside is likely to come from its expanding oncology pipeline and accelerating use of artificial intelligence across R&D. That story begins with the company's push into obesity, where it reported a notable clinical update alongside the quarter. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is expanding rapidly. Data project the global GLP-1 market will grow from $62.2 billion in 2025 to $157 billion by 2035, a compound annual growth rate (CAGR) of about 9.7%. That growth helps explain why billions of dollars are flowing into the industry as companies try to carve out market share. For Pfizer, the opportunity rests largely with its lead GLP-1 candidate, MET-097i. The company announced results from its Phase 2b VESPER-3 study: the trial met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also reported that patients continued to lose weight after transitioning from weekly to monthly dosing, with no plateau observed by the end of the 28-week period. The Growth Driver Investors May Be Missing Immediately after the report, conventional wisdom credited the positive clinical trial results for the stock's gain. That may be true, but investors should recognize that GLP-1 enthusiasm can be a short-term catalyst. While Pfizer's obesity program shows promise, it will take time for sales to flow through to the company's balance sheet. The GLP-1 trade is also broadening, and as recent results from Eli Lilly & Co. (NYSE: LLY) demonstrate, the largest players aren't ceding market leadership. There are other reasons to be bullish on PFE—chiefly its oncology portfolio. Business Research Insights values the global oncology drugs market at roughly $264.92 billion in 2026, projected to climb to $648.08 billion by 2035, a CAGR of about 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer had roughly 60 candidates in its pipeline, representing many opportunities to capture market share. The portfolio was materially strengthened by its acquisition of Seagen in 2023. Today, Pfizer's late-stage portfolio includes candidates such as Vepdegestrant, a next-generation targeted protein degrader (PROTAC), and atirmociclib, a selective CDK4 inhibitor—both aimed at treating ER+/HER2- metastatic breast cancer in later-stage trials. Pfizer also has several other candidates in late-stage testing, including: - Sigvotatug vedotin, an antibody-drug conjugate (ADC) in Phase 3 testing (e.g., BE6A LUNG-01) for metastatic non-small cell lung cancer, leveraging Pfizer's Seagen-acquired ADC expertise.
- Sasanlimab, a PD-1 inhibitor being evaluated for bladder cancer.
- PF-4404, a bispecific PD-1xVEGF agent being combined with Padcev to treat urothelial cancer, positioning it as a potential blockbuster if trials succeed.
Beyond the possibility of multiple product approvals over the next five to 10 years, Pfizer's commitment to artificial intelligence (AI) adds another layer to the investment case. AI is becoming essential across the biopharmaceutical sector. Pfizer integrates AI across R&D through partnerships with firms such as Boltz for biomolecular modeling, XtalPi for molecular design, and Data4Cure for oncology data analytics. These tools—alongside internal platforms like "Charlie" and discovery collaborations with NVIDIA (NASDAQ: NVDA)—help speed target identification and other discovery activities, with some tools reportedly reducing timelines by 50% or more. These efforts were critical to the rapid development of Paxlovid and support Pfizer's 2026 catalysts in oncology and obesity. Pfizer is targeting $1.2 billion in savings by 2027 from efficiency gains tied to AI and other process improvements. Industry-wide, AI is projected to boost productivity by 35% to 45% by improving preclinical decision-making and trial design, making it a core competitive advantage rather than optional hype. Pfizer's early and broad adoption of these tools should be a tailwind for investors over the medium and long term.
| 
